|
Miltenyi Biotec
rea1297 Rea1297, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/10__1172_slash_jci173096-244-28-29 Average 93 stars, based on 1 article reviews
rea1297 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
ACROBiosystems
anti human fmc63 scfv Anti Human Fmc63 Scfv, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/FITC-Labeled+Monoclonal+Anti-FMC63+scFv+Antibody%2C+Mouse+IgG1+(Y45)+DMF+Filed/pm42805174-813-6-10 Average 95 stars, based on 1 article reviews
anti human fmc63 scfv - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Novus Biologicals
fmc63 cd19 ![]() Fmc63 Cd19, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/CD19+Antibody+(FMC63)+%5BPE%5D/pm35755944-198-39-45 Average 91 stars, based on 1 article reviews
fmc63 cd19 - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
Novus Biologicals
il 10 ![]() Il 10, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/CD19+Antibody+(FMC63)+-+Azide+and+BSA+Free/pm40721618-59-7-20 Average 93 stars, based on 1 article reviews
il 10 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
cd19 car fmc63 idiotype antibody apc ![]() Cd19 Car Fmc63 Idiotype Antibody Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/CD19+CAR+FMC63+Idiotype+Antibody%2C+REAfinity/pmc09886226-98-5-10 Average 93 stars, based on 1 article reviews
cd19 car fmc63 idiotype antibody apc - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
ACROBiosystems
mouse igg1 y45 ![]() Mouse Igg1 Y45, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/PE-Labeled+Monoclonal+Anti-FMC63+scFv+Antibody%2C+Mouse+IgG1+(Y45)+(Site-specific+conjugation)+DMF+Filed/pmc09826863-2-5-9 Average 95 stars, based on 1 article reviews
mouse igg1 y45 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Kite Pharma
cdl (anti-fmc63 scfv) mouse mab ![]() Cdl (Anti Fmc63 Scfv) Mouse Mab, supplied by Kite Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/fmc63+28z+car/pmc10862257-64-26-12 Average 90 stars, based on 1 article reviews
cdl (anti-fmc63 scfv) mouse mab - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Acrobio Healthcare Inc
antibody fmc63 clone y45 ![]() Antibody Fmc63 Clone Y45, supplied by Acrobio Healthcare Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/anti+cd19++fmc63++car+immunogenicity+elisa+kit/pm37037829-368-11-17 Average 90 stars, based on 1 article reviews
antibody fmc63 clone y45 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
GenScript corporation
cd19 car-t dna fragments ![]() Cd19 Car T Dna Fragments, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/anti+fmc63+idiotype+antibody/10__1080_slash_2162402x__2022__2114740-73-37-56 Average 90 stars, based on 1 article reviews
cd19 car-t dna fragments - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Celgene
activin receptor-igg1 31 ]." width="250" height="auto" />Activin Receptor Igg1, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/fmc63+igg1/pmc07762162-25-4-15 Average 90 stars, based on 1 article reviews
activin receptor-igg1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Absolute Biotech Inc
cd19-migg2a (fmc63) (ab00613-2.0) ![]() Cd19 Migg2a (Fmc63) (Ab00613 2.0), supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/cd19+migg2a++fmc63+++ab00613+2+0++antibody/pmc08616508-63-0-6 Average 90 stars, based on 1 article reviews
cd19-migg2a (fmc63) (ab00613-2.0) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Eurofins
expect anti-cd19 (fmc63) car t test ![]() Expect Anti Cd19 (Fmc63) Car T Test, supplied by Eurofins, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/fmc63/expect+anti+cd19++fmc63++car+t+test/pmc11962766-29-7-3 Average 90 stars, based on 1 article reviews
expect anti-cd19 (fmc63) car t test - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Molecular therapy. Methods & clinical development
Article Title: Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus.
doi: 10.1016/j.omtm.2022.05.006
Figure Lengend Snippet: Figure 3. Immunophenotyping of 1D3-CD19CAR- GFP (blue, circle), FMC63-CD19CAR-GFP (red, square), or control (GFP only, green, triangle) trans- duced T cells in peripheral blood of treated mice Values shown are the percentage of total CD3+, CD90.2+
Article Snippet: In order to verify the ability for both the 1D3-and FMC63-CD19CAR to target the mouse CD19 antigen, the A20 cells were incubated with 10, 1, 0.1, 0.001, or 0 mg/mL of either the 1D3CD19-blocking antibody (152402, BioLegend) or the
Techniques: Control
Journal: Frontiers in Immunology
Article Title: Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity
doi: 10.3389/fimmu.2022.1058126
Figure Lengend Snippet: Univariate analysis of ICANS.
Article Snippet: Cells were stained with the
Techniques: Biomarker Discovery
Journal: STAR Protocols
Article Title: Inducing T cell dysfunction by chronic stimulation of CAR-engineered T cells targeting cancer cells in suspension cultures
doi: 10.1016/j.xpro.2022.101954
Figure Lengend Snippet:
Article Snippet: PE-labeled Monoclonal Anti-FMC63 scFv Antibody,
Techniques: Recombinant, Reverse Transcription, Software, Pore Size, Flow Cytometry, Transfection
31 ]." width="100%" height="100%">
Journal: Pharmaceutics
Article Title: Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals
doi: 10.3390/pharmaceutics12121184
Figure Lengend Snippet: Biopharmaceuticals and their clinical indications approved by the FDA in 2018–2020 [
Article Snippet: Reblozyl , Luspatercept ,
Techniques: Infection
Journal: Cancers
Article Title: Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy
doi: 10.3390/cancers13225817
Figure Lengend Snippet: EGFR expression is elevated in CRC tumors and anti-EGFR Ab treatment reduces fecal occult blood levels in AOM/DSS-treated mice. ( a ) Schematic overview of induction of colitis-driven colorectal carcinomas by AOM/DSS treatment in female C57BL/6J mice ( n = 88) between days 0 and 70. Control mice received PBS instead of AOM/DSS ( n = 19) between days 0 and 70. At day 70, indicator mice ( n = 9 AOM/DSS-treated; n = 8 PBS-treated) were sacrificed and tissues were sampled for further analysis. Remaining AOM/DSS-treated mice were further subdivided at day 70 into two different dietary intervention groups receiving control diet (CD; n = 39) or glucose-free, high-protein diet (GFHPD; n = 40) until day 126. Dietary interventions were performed in the presence or absence of weekly intraperitoneal ( i.p. ) application of PBS ( n = 9 CD; n = 9 GFHPD), anti-EGFR Ab ( n = 15 CD; n = 16 GFHPD) or a ctrl. antibody ( n = 15 CD; n = 15 GFHPD) between day 70 and 126. PBS-treated control mice were fed either CD ( n = 5) or GFHPD ( n = 6) between day 70 and 126. AOM = azoxymethane; DSS = dextran sodium sulfate; anti-EGFR-mAb = 7A7-mIgG2a; isotype ctrl. mAb = irrelevant mIgG2a; mAb = monoclonal Ab. ( b ) Concentration-dependent binding of anti-EGFR-mIgG2a or ctrl.-mIgG2a to recombinant murine EGFR was analyzed by ELISA experiments. Mean ± SEM of three independent experiments is presented. ( c ) Disease activity index (DAI) of AOM/DSS-treated mice ( n = 88) from day 0 to 70. ( d ) Representative images of endoscopy analyses of AOM/DSS or PBS-treated indicator mice at day 70. ( e ) Egfr mRNA expression was quantified by qPCR and related to Actb mRNA expression in normal or tumor colonic tissues collected from AOM/DSS-treated mice at day 70. Grey dotted line indicates median values of PBS-treated control mice at day 70 (left panel). Representative images of immunohistochemistry staining of EGFR in paraffin-embedded normal and tumor colonic biopsies ( n = 3 each) were collected from AOM/DSS-treated mice at day 70 (right panel). Scale bar = 50 µM. ( f – h ) Body weight, food consumption, and water consumption were routinely monitored between days 70 and 126. ( i ) Fecal occult blood was determined every second day using a hemoccult test. Results are presented as the area under the curve (AUC) from analyzed mice. * p ≤ 0.05, ** p ≤ 0.01. **** p ≤ 0.0001.
Article Snippet:
Techniques: Expressing, Concentration Assay, Binding Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Activity Assay, Immunohistochemistry, Staining
Journal: Cancers
Article Title: Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy
doi: 10.3390/cancers13225817
Figure Lengend Snippet: GFHPD and anti-EGFR Ab treatment reduce tumoral Pd-l1 expression and PD-1 expressing T cells. ( a – d ) QPCR analyses were performed to quantify mRNA expression level of Cd45 , Cd3e , Cd4 , Cd8a , Cd69 , Bcma , F4/80 , Ly6g , Pd-1 , Pd-l1 , Ctla4 , Cd80 , or Cd86 in colonic tissues collected from indicated treatment groups of AOM/DSS mice. Results are based on ΔCT calculation including relation to β-actin mRNA expression. Heatmap was generated based on normalized values (%) per transcript. The mean value per group is presented. n = 6–7 ctrl. Ab and CD; n = 6–7 anti-EGFR Ab and CD; n = 4–6 ctrl. Ab and GFHPD; n = 6–9 anti-EGFR Ab and GFHPD. Red dotted horizontal lines represent respective median values of PBS-treated control mice at day 126. ( e , f ) MC-38 cells were incubated in standard culture medium (25 mM glucose, 1% NEAA) or glucose-free plus 20% NEAA medium for 48 h. ( e ) Pd-l1 mRNA expression was quantified by qPCR experiments and related to Ubc mRNA expression ( n = 5 independent experiments), while ( f ) PD-L1 protein expression was analyzed by Western blot experiments. Alpha-Tubulin expression served as a loading control (representative images of n = 5 independent experiments). ( g ) MC-38 cells were incubated in standard culture medium (25 mM glucose, 1% NEAA) or in glucose-free plus 20% NEAA medium in the presence or absence of either the anti-EGFR Ab 7A7-mIgG2a or the irrelevant control Ab CD19-mIgG2a for 48 h. Pd-l1 mRNA expression was quantified by qPCR experiments and related to Ubc mRNA expression ( n = 3 independent experiments). ( h ) Representative images from spleens collected from AOM/DSS-treated mice at day 126. ( i ) Representative spleen lengths were measured for indicated treatment groups. n = 9 ctrl. Ab and CD; n = 9 anti-EGFR Ab and CD; n = 6 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. Red dotted horizontal line represents median values of PBS-treated control mice at day 126. ( j ) QPCR analyses were performed to quantify mRNA expression levels of Cd45 , Ly6g , F4/80 , Bcma , Cd69 , Cd3e , Cd4 , Cd8a , Ctla4 , and Pd-1 in splenic tissues collected from indicated treatment groups of AOM/DSS mice. Results are based on 2 − ΔCT calculation, including relation to β-actin mRNA expression. Heatmap was generated based on normalized values (%) per transcript. The mean value per group is presented. n = 10 ctrl. Ab and CD; n = 10 anti-EGFR Ab and CD; n = 10 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. ( k ) Splenic CD3e, PD-1, and F4/80 protein expression levels were determined by Western blot experiments. Alpha-Tubulin expression served as a loading control. ( l ) Densitometric analyses were performed using ImageJ software. n = 10 ctrl. Ab and CD; n = 10 anti-EGFR Ab and CD; n = 10 ctrl. Ab and GFHPD; n = 11 anti-EGFR Ab and GFHPD. ( m ) Splenic PD-1 protein expression was related to splenic CD3e protein expression. ( n ) Splenic PD-1 protein expression is displayed in relation to colorectal tumor scores (smaller tumor 0–3; larger tumor 4–5). * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.
Article Snippet:
Techniques: Expressing, Generated, Incubation, Western Blot, Software
Journal: Cancers
Article Title: Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy
doi: 10.3390/cancers13225817
Figure Lengend Snippet: Details of applied primary and secondary antibodies.
Article Snippet:
Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay